olumiant
eli lilly nederland b.v. - baricitinib - artrite, reumatóide - imunossupressores - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant pode ser usado como monoterapia ou em combinação com metotrexato. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.
olumiant
eli lilly do brasil ltda - baricitinibe - agentes antineoplÁsicos e imunomoduladores; antagonistas hormonais e agentes relacionados; inibidores enzimÁticos; terapia endÓcrina
ontozry
angelini pharma s.p.a - cenobamate - epilepsia - antiepilépticos, - adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.
cibinqo
pfizer europe ma eeig - abrocitinib - dermatite, atopic - outras preparações dermatológicas - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.
alunbrig
takeda pharma a/s - brigatinib - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.
evobrig
takeda pharma ltda. - brigatinibe - outros agentes antineoplÁsicos
cibinqo
pfizer brasil ltda - abrocitinibe - imunosupressor
fluconazol
vitamedic industria farmaceutica ltda - fluconazol - antimicoticos sistemicos
zoltec
pfizer brasil ltda - fluconazol - antimicoticos sistemicos
fluconazol
cimed industria s.a - fluconazol - antimicotico